TPCA-1 is a potent IKK-2 inhibitor. TPCA-1 is also an effective inhibitor of STAT3 phosphorylation, DNA binding, and transactivation in vivo. It selectively repressed proliferation of NSCLC cells with constitutive STAT3 activation. TPCA-1 as a direct dual inhibitor for both IKKs and STAT3, whereas treatment targeting EGFR only could not sufficiently repress NF-κB and STAT3 pathways for lung cancers harboring mutant EGFR. Therefore, synergistic treatment of TPCA-1 with TKIs has potential to be a more effective strategy for cancers.
IκB/IKK Inhibitors Related Products:
Resveratrol; BAY 11-7082; IKK-16; BMS-345541; BMS-345541 HCl; SC-514; LY2409881 trihydrochloride; IMD-0354; Bardoxolone methyl; TBK1; WS6; WS3; MRT67307